LearnGlossaryMarketStocksSuperinvestorsSign in

GMAB

Genmab A/S

Healthcare · $21.8B market cap

Verdict

Share price

$34.75

close of Oct 3, 2026

Fair value

$19.84

Sticker Price

Payback Price

$7.94

buy price

Overpriced

GMAB is Overpriced: at $34.75 it trades 75% above its fair value of $19.84. Its buy price (Payback Price) is $7.94, 77% below today's price. Business quality is strong: all 5 key numbers clear the 10% bar.

How we valued it

Free Cash Flow. Sales grew -36% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.

Business quality

5 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth31.5% a year✓
Equity per share growth31.6% a year✓
Sales growth29.4% a year✓
Free cash flow growth26.7% a year✓
Return on invested capital11.7%✓

Follow GMAB

Get notified when it reaches its buy price of $7.94. Free.

Create a free account

About Genmab A/S

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works